5-Fluorouracil Response in a Large Panel of Colorectal Cancer Cell Lines is Associated with Mismatch Repair Deficiency

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Jul 8

PMID 20606684

Citations 51

Authors

K Bracht

A M Nicholls

Y Liu

W F Bodmer

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer is (CRC) one of the commonest cancers and its therapy is still based on few drugs. Currently, no biological criteria are used to choose the most effective of the established drugs for treatment.

Methods: A panel of 77 CRC cell lines was tested for sensitivity to 5-fluorouracil (5FU) using the SRB assay. The responses were grouped into three categories and correlated with genetic changes in the cell lines.

Results: The strongest and most clearcut correlation was between 5-fluorouracil response and replication error status (mismatch repair deficiency). All the other significant correlations (loss of heterozygosity for DCC and mutations in TGFbIIR) are secondary to the association with replication error status.

Interpretation And Conclusion: Our findings validate previous analyses based mainly on clinical data, and indicate that replication error status could be a useful guide to 5-fluorouracil-based CRC therapy. Essentially, all previously described correlations with 5FU response are secondary to the association with replication error status.

Citing Articles

Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA.

Iveland T, Hagen L, de Sousa M, Liabakk N, Aas P, Sharma A Sci Rep. 2025; 15(1):2082.

PMID: 39814799 PMC: 11736037. DOI: 10.1038/s41598-025-86007-w.

Enhanced anticancer effect of thymidylate synthase dimer disrupters by promoting intracellular accumulation.

Marverti G, Moschella M, Belardo A, Lamesta M, Mercanile G, Tagliazucchi L Front Pharmacol. 2024; 15:1477318.

PMID: 39611169 PMC: 11602703. DOI: 10.3389/fphar.2024.1477318.

5-Fluorouracil treatment represses pseudouridine-containing miRNA export into extracellular vesicles.

Qu S, Nelson H, Liu X, Wang Y, Semler E, Michell D J Extracell Biol. 2024; 3(9):e70010.

PMID: 39281020 PMC: 11393769. DOI: 10.1002/jex2.70010.

Overcoming Resistance of Caco-2 Cells to 5-Fluorouracil through Diruthenium Complex Encapsulation in PMMA Nanoparticles.

Coloma I, Parron-Ballesteros J, Cortijo M, Cuerva C, Turnay J, Herrero S Inorg Chem. 2024; 63(28):12870-12879.

PMID: 38833385 PMC: 11256753. DOI: 10.1021/acs.inorgchem.4c01323.

Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies.

Dalisay D, Tenebro C, Sabido E, Suarez A, Paderog M, Reyes-Salarda R Mar Drugs. 2024; 22(3).

PMID: 38535455 PMC: 10972102. DOI: 10.3390/md22030114.

References

Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboue R, Laurent M . Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009; 22(9):1186-95. DOI: 10.1038/modpathol.2009.80. View

Coleman M, Quaresma M, Berrino F, Lutz J, De Angelis R, Capocaccia R . Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9(8):730-56. DOI: 10.1016/S1470-2045(08)70179-7. View

Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino J . Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 2002; 1587(2-3):164-73. DOI: 10.1016/s0925-4439(02)00079-0. View

Arnold C, Goel A, Boland C . Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003; 106(1):66-73. DOI: 10.1002/ijc.11176. View

Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J . Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut. 2005; 55(6):848-55. PMC: 1856227. DOI: 10.1136/gut.2005.073015. View

de la Chapelle A . Microsatellite instability. N Engl J Med. 2003; 349(3):209-10. DOI: 10.1056/NEJMp038099. View

Efstathiou J, Liu D, Wheeler J, Kim H, Beck N, Ilyas M . Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci U S A. 1999; 96(5):2316-21. PMC: 26781. DOI: 10.1073/pnas.96.5.2316. View

Yeung T, Gandhi S, Wilding J, Muschel R, Bodmer W . Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A. 2010; 107(8):3722-7. PMC: 2840416. DOI: 10.1073/pnas.0915135107. View

Riely G, Ladanyi M . KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn. 2008; 10(6):493-5. PMC: 2570631. DOI: 10.2353/jmoldx.2008.080105. View

10.

Vichai V, Kirtikara K . Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2007; 1(3):1112-6. DOI: 10.1038/nprot.2006.179. View

11.

Kinsella A, Lepts G, Hill C, Jones M . Reduced E-cadherin expression correlates with increased invasiveness in colorectal carcinoma cell lines. Clin Exp Metastasis. 1994; 12(4):335-42. DOI: 10.1007/BF01753841. View

12.

Douglas E, Fiegler H, Rowan A, Halford S, Bicknell D, Bodmer W . Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res. 2004; 64(14):4817-25. DOI: 10.1158/0008-5472.CAN-04-0328. View

13.

Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N . Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol. 2005; 16 Suppl 4:iv44-49. DOI: 10.1093/annonc/mdi907. View

14.

Etienne-Grimaldi M, Formento J, Francoual M, Francois E, Formento P, Renee N . K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008; 14(15):4830-5. DOI: 10.1158/1078-0432.CCR-07-4906. View

15.

Bracht K, Boubakari , Grunert R, Bednarski P . Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data. Anticancer Drugs. 2005; 17(1):41-51. DOI: 10.1097/01.cad.0000190280.60005.05. View

16.

Popat S, Hubner R, Houlston R . Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23(3):609-18. DOI: 10.1200/JCO.2005.01.086. View

17.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J . Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268(5215):1336-8. DOI: 10.1126/science.7761852. View

18.

Rutzky L, Kaye C, Siciliano M, Chao M, Kahan B . Longitudinal karyotype and genetic signature analysis of cultured human colon adenocarcinoma cell lines LS180 and LS174T. Cancer Res. 1980; 40(5):1443-8. View

19.

Muller C, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A . Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 2008; 23(11):1033-9. DOI: 10.1007/s00384-008-0504-2. View

20.

Rim S, Seeff L, Ahmed F, King J, Coughlin S . Colorectal cancer incidence in the United States, 1999-2004 : an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(9):1967-76. DOI: 10.1002/cncr.24216. View